Literature DB >> 24469391

Acute thrombotic thrombocytopenic purpura after pneumococcal vaccination.

Yuki Kojima1, Haruhiko Ohashi, Tomonobu Nakamura, Hiroyuki Nakamura, Hideyuki Yamamoto, Yasuhiko Miyata, Hiroatsu Iida, Hirokazu Nagai.   

Abstract

We report the case of a 68-year-old woman with acute thrombotic thrombocytopenic purpura (TTP) that developed after pneumococcal vaccination. She was found in a confusional state with high fever 15 days after vaccination. Laboratory data showed hemolytic anemia and thrombocytopenia, and blood smear showed fragmented erythrocytes. TTP was diagnosed based on the clinical presentation, and was subsequently confirmed by the absence of ADAMTS13 activity and the presence of inhibitor against ADAMTS13 in serum. She was successfully treated using plasma exchange and corticosteroids, and no recurrence has been identified. This appears to represent the first report of TTP following pneumococcal vaccination.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24469391     DOI: 10.1097/MBC.0000000000000058

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  18 in total

1.  Acquired thrombotic thrombocytopenic purpura after AstraZeneca vaccine: A case report.

Authors:  Fatemeh Yaghoubi; Davood Dalil
Journal:  Caspian J Intern Med       Date:  2022

2.  Recurrence of Thrombotic Thrombocytopenic Purpura After Vaccination with mRNA-1273 COVID-19 vaccine.

Authors:  Spyridon Ntelis; Kathryn Champ
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-07-04

3.  SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura.

Authors:  Hridaya Shah; Ann Kim; Senthil Sukumar; Marshall Mazepa; Ruhail Kohli; Evan M Braunstein; Robert A Brodsky; Spero Cataland; Shruti Chaturvedi
Journal:  Blood       Date:  2022-04-21       Impact factor: 25.476

4.  First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination.

Authors:  Sévérine de Bruijn; Marie-Berthe Maes; Laure De Waele; Karen Vanhoorelbeke; Alain Gadisseur
Journal:  J Thromb Haemost       Date:  2021-07-05       Impact factor: 16.036

Review 5.  A New Classification System for IgG4 Autoantibodies.

Authors:  Inga Koneczny
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

6.  Immune Thrombotic Thrombocytopenic Purpura following Pfizer-BioNTech anti-COVID-19 vaccination in a patient healed from lymphoma after allogeneic hematopoietic stem cell transplantation.

Authors:  Vanessa Innao; Salvatore Urso; Monica Insalaco; Albino Borraccino; Ugo Consoli
Journal:  Thromb Res       Date:  2022-01-04       Impact factor: 3.944

Review 7.  Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.

Authors:  Syed Hamza Bin Waqar; Anosh Aslam Khan; Shehzeen Memon
Journal:  Int J Hematol       Date:  2021-07-15       Impact factor: 2.490

8.  Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine.

Authors:  Hannah Maayan; Ilya Kirgner; Odit Gutwein; Katrin Herzog-Tzarfati; Naomi Rahimi-Levene; Maya Koren-Michowitz; Dorit Blickstein
Journal:  J Thromb Haemost       Date:  2021-07-07       Impact factor: 16.036

9.  Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-Oxford COVID-19 vaccine.

Authors:  Mona Al-Ahmad; Mona Al-Rasheed; Neveen Abo Bakr Shalaby
Journal:  EJHaem       Date:  2021-05-18

10.  Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine.

Authors:  Johannes Ruhe; Ulf Schnetzke; Karim Kentouche; Florian Prims; Michael Baier; Konstantin Herfurth; Mandy Schlosser; Martin Busch; Andreas Hochhaus; Gunter Wolf
Journal:  Ann Hematol       Date:  2021-07-26       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.